Literature DB >> 25328140

Sparing of orexin-A and orexin-B neurons in the hypothalamus and of orexin fibers in the substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated macaques.

Manale Bensaid1, Dominique Tandé, Véronique Fabre, Patrick P Michel, Etienne C Hirsch, Chantal François.   

Abstract

Several studies conducted in patients with Parkinson's disease have reported that the degeneration of substantia nigra dopaminergic neurons, which are essential for motor control, is associated with the loss of hypothalamic orexin neurons, which are involved in sleep regulation. In order to better explore the mutual interactions between these two systems, we wished to determine in macaques: (i) if the two orexin peptides, orexin-A and orexin-B, are distributed in the same hypothalamic cells and if they are localized in nerve terminals that project onto nigral dopaminergic neurons, and (ii) if there is a loss of orexin neurons in the hypothalamus and of orexin fibers innervating nigral dopaminergic neurons in macaques rendered parkinsonian by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) intoxication. We showed that virtually all cells stained for orexin-A in the hypothalamus co-expressed orexin-B. Numerous terminals stained for both orexin-A and orexin-B immunoreactivity that innervated the whole extent of the ventral tegmental area and substantia nigra pars compacta were found in close proximity to tyrosine hydroxylase-immunoreactive dendrites. These data indicate that orexin-A and orexin-B peptides are in a position to play a role in controlling the activity of nigral dopaminergic neurons. However, no loss of orexin-A or orexin-B neurons in the hypothalamus and no loss of orexin fibers in the substantia nigra pars compacta was found in MPTP-treated macaques when compared with control macaques. We conclude that a relatively selective dopaminergic lesion, such as that performed in MPTP-treated macaques, is not sufficient to induce a loss of hypothalamic orexin neurons.
© 2014 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.

Entities:  

Keywords:  Parkinson's disease; dopaminergic neurons; hypocretin; orexin projections

Mesh:

Substances:

Year:  2014        PMID: 25328140     DOI: 10.1111/ejn.12761

Source DB:  PubMed          Journal:  Eur J Neurosci        ISSN: 0953-816X            Impact factor:   3.386


  4 in total

1.  Basal ganglia beta oscillations during sleep underlie Parkinsonian insomnia.

Authors:  Aviv D Mizrahi-Kliger; Alexander Kaplan; Zvi Israel; Marc Deffains; Hagai Bergman
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-07       Impact factor: 11.205

Review 2.  Exploring the Role of Orexinergic Neurons in Parkinson's Disease.

Authors:  Sachin Kumar; Tapan Behl; Aayush Sehgal; Sukhbir Singh; Neelam Sharma; Saurabh Bhatia; Ahmed Al-Harassi; Mohammed M Abdel-Daim; Simona Bungau
Journal:  Neurotox Res       Date:  2021-09-08       Impact factor: 3.911

3.  Orexin-A Exerts Neuroprotective Effects via OX1R in Parkinson's Disease.

Authors:  Mei-Fang Liu; Yan Xue; Cui Liu; Yun-Hai Liu; Hui-Ling Diao; Ying Wang; Yi-Peng Pan; Lei Chen
Journal:  Front Neurosci       Date:  2018-11-15       Impact factor: 4.677

4.  Early High-Fat Diet Exposure Causes Dysregulation of the Orexin and Dopamine Neuronal Populations in Nonhuman Primates.

Authors:  Cadence True; Anam Arik; Sarah Lindsley; Melissa Kirigiti; Elinor Sullivan; Paul Kievit
Journal:  Front Endocrinol (Lausanne)       Date:  2018-09-10       Impact factor: 6.055

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.